Search Result

Results for "

dermatological conditions

" in MedChemExpress (MCE) Product Catalog:

標的別:	Antibiotic (2) Bacterial (3) CCR (2) Environmental Pollutants (1) Fungal (2) Histamine Receptor (1) Lipoxygenase (1) Reference Standards (1) STAT (1)
研究分野別:	Infection (3) Inflammation/Immunology (7)

阻害剤およびアゴニスト

スクリーニングライブラリ

天然物

製品番号	製品名	Target	研究分野	構造式

HY-N7123

Sulfacetamide 3 Publications Verification Sulphacetamide	Environmental Pollutants Antibiotic Bacterial Fungal	Infection Inflammation/Immunology
Sulfacetamide (Sulphacetamide) is a sulfonamide antibiotic. Sulfacetamide has antifungal and antibacterial activities. Sulfacetamide is employed as a topical formulation in various ophthalmic, dermatological, and hair solutions against bacterial infections, acne and scalp conditions. Sulfacetamide targets bacterial folic acid synthesis and is effective against various gram-positive and gram-negative bacteria. Sulfacetamide inhibits the synthesis of both dihydro-folic acid and para-aminobenzoic acid. Sulfacetamide can be used for the study of ocular infections .

HY-19443

UCB-35440	Histamine Receptor Lipoxygenase	Inflammation/Immunology
UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 can be used for the research of dermatologic inflammatory conditions .

HY-N7123R

Sulfacetamide (Standard) Sulphacetamide (Standard)	Reference Standards Antibiotic Bacterial Fungal	Infection Inflammation/Immunology
Sulfacetamide (Standard) (Sulphacetamide (Standard)) is the analytical standard of Sulfacetamide (HY-N7123). This product is intended for research and analytical applications. Sulfacetamide (Sulphacetamide) is a sulfonamide antibiotic. Sulfacetamide has antifungal and antibacterial activities. Sulfacetamide is employed as a topical formulation in various ophthalmic, dermatological, and hair solutions against bacterial infections, acne and scalp conditions. Sulfacetamide targets bacterial folic acid synthesis and is effective against various gram-positive and gram-negative bacteria. Sulfacetamide inhibits the synthesis of both dihydro-folic acid and para-aminobenzoic acid. Sulfacetamide can be used for the study of ocular infections .

HY-185145

CCL17-IN-2	CCR	Inflammation/Immunology
CCL17-IN-2 (Compound Ex.128) is a CCL17 secretion inhibitor with an EC₅₀ of 0.3 nM. CCL17-IN-1 can be used in the research of autoimmune diseases, dermatological conditions, and respiratory disorders .

HY-185073

STAT6-IN-11	STAT	Inflammation/Immunology
STAT6-IN-11 is a STAT6 inhibitor with an EC₅₀ of 0.006 μM. STAT6-IN-11 can be used for the research of dermatological condition or respiratory conditions .

HY-N18789

Tagetes oil	Bacterial	Infection Inflammation/Immunology
Tagetes oil is an organic essential oil extracted from the Tagetes plant exhibiting inherent anti-inflammatory and antimicrobial attributes. Its employment in the research of diverse skin infections, wounds and dermatological conditions has been extensively recognized.

HY-185144

CCL17-IN-1	CCR	Inflammation/Immunology
CCL17-IN-1 (Compound Ex.132) is a CCL17 secretion inhibitor with an EC₅₀ of 0.2 nM. CCL17-IN-1 can be used in the research of autoimmune diseases, dermatological conditions, and respiratory disorders .

製品番号	製品名

HY-L022M

FDA-Approved Drug Library Mini	3,220 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,220 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

FDA-Approved Drug Library Mini

3,220 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,220 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

製品番号	製品名	Category	Target	構造式

HY-N7123

Sulfacetamide 3 Publications Verification Sulphacetamide	Infection Classification of Application Fields Disease Research Fields	Environmental Pollutants Antibiotic Bacterial Fungal
Sulfacetamide (Sulphacetamide) is a sulfonamide antibiotic. Sulfacetamide has antifungal and antibacterial activities. Sulfacetamide is employed as a topical formulation in various ophthalmic, dermatological, and hair solutions against bacterial infections, acne and scalp conditions. Sulfacetamide targets bacterial folic acid synthesis and is effective against various gram-positive and gram-negative bacteria. Sulfacetamide inhibits the synthesis of both dihydro-folic acid and para-aminobenzoic acid. Sulfacetamide can be used for the study of ocular infections .

HY-N18789

Tagetes oil	Structural Classification Extract	Bacterial
Tagetes oil is an organic essential oil extracted from the Tagetes plant exhibiting inherent anti-inflammatory and antimicrobial attributes. Its employment in the research of diverse skin infections, wounds and dermatological conditions has been extensively recognized.

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

お名前
メール *

	Sorry, but the email address you supplied was invalid.